# Aflibercept

## Eylea aflibercept 2mg/0.05mL

| TAH Drug Code      | [IEYL](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEYL)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | ‧ Indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). ‧ Visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). ‧ Visual impairment due to diabetic macular edema (DME). ‧ Visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). ‧ Treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathological myopia (PM).                                                                                                                                                                                                                                                                                 |
| Dosing             | Wet type (Neovascular) of age-related macular degeneration (wAMD): 2 mg every 4 weeks for the first 3 injections then every 8 weeks thereafter. Macular edema following central retinal vein occlusion (CRVO): 2 mg every 4 weeks via IVIA. Diabetic macular edema: 2 mg every 4 weeks for the first 5 injections， followed by 2 mg every 8 weeks. Macular edema induced visual impairment following branch retinal vein occlusion (BRVO): 2 mg every 4 weeks for the first 6 injections， followed by 2 mg every 8 weeks. Choroidal neovascularization(CNV) following pathological myopia: 2 mg single dose via IVIA. May repeat 1 to 3 times a year with the 1 month- interval according to the doctor's judgment on vision and/or anatomy. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | 1.Ocular or periocular infection 2.Active intraocular inflammation 3.Hypersensitivity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common: Blurred vision (1-7%)， Cataract (Adult， up to 19%; pediatric， 1%)， Conjunctival hemorrhage (Adult， 1-31%; pediatric， 5-9%)， Corneal erosion (1-7%)， Foreign body sensation， In eyes (Up to 4%)， Pain in eye (4-13%)， Retinal hemorrhage (1-4%)， Visual discomfort， Vitreous floaters (1-8%) Serious: Myocardial infarction， Arterial thrombosis (0.4-6.4%)， Hypersensitivity reaction (Less than 1%)， Cerebrovascular accident， Endophthalmitis (Less than 1%)， Raised intraocular pressure (1-9%)， Retinal detachment (Up to 6%)， Retinal pigment epithelial detachment (1-5%)， Retinal venous tortuosity， Vitreous detachment (1-8%)                                                                           |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/aflibercept-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

